Senior Management

Donald J. Elmer, Interim CEO and Chairman of the Board

Mr. Elmer is the managing general partner of Pacific Horizon Ventures. He is currently a board member of Illumigen Biosciences, iScience Interventionaland Novocell. He has extensive prior board experience and has successful operational experience over a twelve-year period in early-stage technology companies, including Cascadia Technology Corporation-a medical electronics company-and Cygnet Systems Corporation-a software developer. Mr. Elmer received his M.A. in Economics from the University of Pennsylvania.

John Reno, Ph.D., Chief Operating Officer

Dr. Reno has over twenty years experience in pharmaceutical development. He has been president of Perlan Therapeutics, chief operating officer of IBC Pharmaceuticals, and vice president research & development and general manager oncology for NeoRx Corporation. While at NeoRx, he was part of the leadership that gained FDA approval for the company's first drug. Dr. Reno obtained his Ph.D. in biochemistry from Michigan State University where he discovered a drug approved for the treatment of herpes virus infections. He is an inventor on 42 issued US patents.

Stephen Becker, M.D., Chief Medical Officer

Dr. Becker joined Koronis in 2006 from AnorMED, where he served as medical director and safety officer, clinical development. At AnorMED, Dr. Becker directed the clinical development program for the company's HIV entry inhibitor and stem cell mobilization programs. Dr. Becker brings nearly 30 years of medical and research experience to the Company. Dr. Becker has served as principal investigator for numerous HIV trials and directed large multi-site, collaborative research studies in HIV including the Collaborations in HIV Outcomes Research (CHORUS) study, which involved more than 8,000 HIV patients. From 1980 to 2005 he served on the faculty at the University of California, San Francisco School of Medicine and led a practice specializing in HIV treatment. Dr. Becker received his M.D. from State University of New York at Buffalo, School of Medicine and an A.B. in psychology from University of Pennsylvania.

Origins
The development of KP-1461 stems from the leading research of Larry Loeb, University of Washington, John Essigmann, Massachusetts Institute of Technology, and Jim Mullins, University of Washington. These researchers reduced to practice -- through the development of Viral Decay Acceleration™™ -- a theory originally conceived by Nobel laureate Manfred Eigen. Eigen described the complex and dynamic nature of viruses as “quasispecies,” and introduced the idea that it may be possible to defeat a virus by exploiting its complex, rapidly mutating form.

Intellectual Property

Koronis has established a strong intellectual property position related to Viral Decay Acceleration™™ (VDA) and KP-1461. This patent portfolio includes five issued U.S. patents related to VDA and an allowed patent related to the use and composition of KP-1461.